Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lumosa Therapeutics Co's enterprise value is NT$11,905.77 Mil.
Lumosa Therapeutics Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-364.01 Mil. Therefore, Lumosa Therapeutics Co's EV-to-EBITDA for today is -32.71.
The historical rank and industry rank for Lumosa Therapeutics Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6535'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -188.59 Med: -27.49 Max: 35.64
Current: -32.71
During the past 13 years, the highest EV-to-EBITDA of Lumosa Therapeutics Co was 35.64. The lowest was -188.59. And the median was -27.49.
ROCO:6535's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 14.15
vs ROCO:6535: -32.71
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Lumosa Therapeutics Co (ROCO:6535) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lumosa Therapeutics Co's PE Ratio (TTM) for today is calculated as:
Lumosa Therapeutics Co's share price for today is NT$74.80.
Lumosa Therapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-2.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6535 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Lumosa Therapeutics Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumosa Therapeutics Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lumosa Therapeutics Co's EV-to-EBITDA falls into.
Lumosa Therapeutics Co's current Enterprise Value is NT$11,905.77 Mil.
Lumosa Therapeutics Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-364.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumosa Therapeutics Co (ROCO:6535) has a EV-to-EBITDA of -32.71 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lumosa Therapeutics Co. According to the industry distribution chart, Lumosa Therapeutics Co ranks #999999 out of 401 companies in the Biotechnology industry.
Is Lumosa Therapeutics Co's EV-to-EBITDA too high?
Lumosa Therapeutics Co's current EV-to-EBITDA is -32.71. Based on the distribution chart, Lumosa Therapeutics Co ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lumosa Therapeutics Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lumosa Therapeutics Co ranks #999999 out of 401 companies for EV-to-EBITDA. This places Lumosa Therapeutics Co in the lower half of its industry. The industry median EV-to-EBITDA is 14.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.15, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lumosa Therapeutics Co. For the Biotechnology industry, the median EV-to-EBITDA is 14.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumosa Therapeutics Co's current EV-to-EBITDA is -32.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$138.36, compared to a current price of NT$74.80 — trading 45.9% below its estimated fair value. The current EV-to-EBITDA is -32.71. Lumosa Therapeutics Co's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current EV-to-EBITDA is -32.71 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?
Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued.
The current stock price of NT$74.80 is trading 45.9% below its estimated GF Value™ of NT$138.36.
GuruFocus considers Lumosa Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6535:
EV-to-EBITDA: -32.71
GF Value™: NT$138.36 vs. price of NT$74.80 (45.9% below fair value)
No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
64GF Score
Get the complete analysis for ROCO:6535
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6535 has been successfully added to your 
